Although we take the Government’s state of emergency seriously, in order not to pause our first cancer screening test N-NOSE completely, we continue the analysis in our analysis center and three R&D centers while taking necessary steps to prevent infection.
To support our employees to cope with the situation, we have decided to reward them with lump-sum payments (JPY 30,000 per employee).
We will continue to focus on our efforts to expand N-NOSE tests so that we can provide it for as many people as possible.
TOKYO, JAPAN – March 6, 2026 – HIROTSU Bio Science Inc. announced the establishment of a new U.S. subsidiary, Hirotsu Global Inc., effectively c . . .
2026.03.06FOR IMMEDIATE RELEASE HIROTSU Bio Science Announces Referral of Former Employee to Prosecutors for Violation of the Unfair Competition Preven . . .
2026.02.05A novel, non-invasive approach to detecting micro-distant metastasis in highly lethal pancreatic cancer. TOKYO, JAPAN – January 5, 2026 – HIR . . .
2026.01.05